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Abstract
The number of patients experiencing agitation, delirium, or opiate withdrawal 
symptoms is increasing exponentially. Geriatric delirium is a condition that 
can be difficult to treat. The epidemic of opiate use, and subsequent 
withdrawal sequela, presents as psychosis, agitation, combativeness. 
Treatment of these symptoms using antipsychotic drugs is not without 
complications. One possible medication side effect, Neuroleptic Malignant 
Syndrome (NMS), is characterized as a life-threatening emergency whose 
presenting symptoms include a decreased level of consciousness, muscle 
rigidity, neuroleptic malignant hyperthermia and autonomic dysfunction. 
Identification of NMS is often overlooked in lieu of more routine conditions 
such as seizure, sepsis, delirium and withdrawal agitation. Delay in the 
identification and definitive treatment of NMS can be life-threatening. This 
offering will present two case studies which highlight the pathophysiology 
of NMS, discuss the medications implicated in its development, review 
disease signs and symptoms, and outline available treatment options. 
Information gained during this presentation can be incorporated within  
a wide variety of settings to safely care for the neuroscience patient.
Objectives
1.  Review the pathophysiology of neuroleptic malignant syndrome  
(NMS) in the neuroscience patient with severe illness.
 2.  Discuss the medications that can cause of NMS and associated  
signs and symptoms.
 3.  Outline the treatment interventions for NMS.
 4.  Detail two case studies that illustrate the difficulty of definitive  
diagnosis of NMS and the devastating consequences.
Background and Pathophysiology
1.  Epidemiology
 a.  Incidence rate 0.02 to 3% among patients taking antipsychotic 
medications
 b.  Mortality is estimated to be 10-20%
2.  Pathophysiology
 a.  Dopamine receptor blockade due to medication administration
  •  Hypothalamus disruption causing hyperthermia, muscle tremor, 
muscle rigidity
 b.  Genetic defect of dopamine receptors
  • Defect in the sympathetic nervous system
  •  Hyperexcited state can lead to hyperthermia
 c.  Stacked doses of antipsychotic drugs to lessen symptoms of 
agitation, combativeness, delirium
  • Missed early signs due to diagnosis bias 
  • Differential diagnoses
Medications that may cause neuroleptic malignant 
syndrome
 a.  Antipsychotics: Haloperidol, Risperidone, Seroquel, Zyprexa
 b.  Antidepressants: Wellbutrin, Amoxapine, Desipramine
 c.  Benzodiazepines: Valium, Midazolam, Ativan
 d.  Antiemetics: Metoclopramide, Ondansetron
Signs and symptoms of neuroleptic malignant syndrome
 a.  Decreased level of consciousness
 b.  Body temperature > 38°C
Treatment interventions for neuroleptic malignant syndrome
 a.  Aggressive treatment of hyperthermia
 b.  Iced gastric lavage
 c.  Supportive care for hemodynamic/respiratory compromise
  •  Intubation with mechanical ventilation
  •  Vasoactive medications to maintain MAP> 60-65
 d.  Dantrolene
 e.  Bromocriptine
Traumatic fall: 61-year-old female
 a.  Baseline is confusion
 b.  Agitation and combativeness on 
hospital day 2 
 c.  Family admitted patient has alcohol 
dependency and severe anxiety
 d.  Medications over next 4 days 
included Haldol, Wellbutrin, Paxil, 
Ativan, Midazolam, Thiamine, Zyprexa
 e.  Muscle rigidity/shaking on hospital 
day 4 
 f.  Developed decreased level of 
consciousness (stupor) and    
temperature of  42.2°C (108°F).
 g.  Comatose
 h.  Dantrolene infusion/Bromocriptine 
begun
 i.  Targeted temperature management  
Patient transitioned to comfort measures. 
Covid-19: 40-year-old female
 a.  Intubated
 b.  Toxicology – Amphetamines and 
Methamphetamines
 c.  Agitation and combativeness on 
hospital day 4 
 d.  Fentanyl and Midazolam continuous 
infusions
 e.  PRN doses of Diazepam and 
Lorazepam 
 f.  Hospital stay day 10 developed 
increasing temperature. from  
38.6°C (101.5°F) to 43.3°C (110°F) – 
Comatose
 g.  Dantrolene infusion and 
Bromocriptine begun
 h.  Targeted temperature management 
 i.   Code blue protocol initiated
Patient pronounced 6 hours after initial 
temperature rise.
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